Loading...

GERN GERON CORP Earnings Reports 8-K Filing

GRN

GRN

GERON CORP

(GERN)

2025 8-K

Director Elections

Earnings Report

Financial Guidance Update

Loan Amendment Update

Workforce Reduction

Quarterly Results

Financial Statements

Management Changes

Financial Statements

Management Change

Management Changes

Financial Results

Earnings Guidance

Funding Agreements

Earnings Reports

FDA Approval for RYTELOTM

Annual Meeting of Stockholders

Earnings Report

Underwriting Agreement

Results of FDA Advisory Com...

Results of Operations and F...

Financial Condition

Amendment and Restatement o...

Appointment of New Director

Entry into a Material Defin...

Appointment of CFO

Earnings Report

Annual Meeting and Amendments

Earnings Reports

Conference Participation

External Links:

Geron Corp expects fourth quarter 2024 U.S. sales of RYTELO to be around $45-46 million, with operating expenses of $250-260 million and cash reserves of approximately $500 million as of December 31, 2024, to be discussed at the J.P. Morgan Healthcare Conference in January 2025.

AI Assistant

GERON CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.